OmniAb (NASDAQ:OABI – Get Free Report) is one of 38 public companies in the “Commercial physical research” industry, but how does it contrast to its peers? We will compare OmniAb to related companies based on the strength of its risk, analyst recommendations, earnings, profitability, valuation, dividends and institutional ownership.
Institutional and Insider Ownership
56.5% of OmniAb shares are owned by institutional investors. Comparatively, 51.7% of shares of all “Commercial physical research” companies are owned by institutional investors. 7.0% of OmniAb shares are owned by company insiders. Comparatively, 15.4% of shares of all “Commercial physical research” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Earnings and Valuation
This table compares OmniAb and its peers gross revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| OmniAb | $66.12 million | -$22.33 million | -24.57 |
| OmniAb Competitors | $1.60 billion | $64.76 million | 2.50 |
Profitability
This table compares OmniAb and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| OmniAb | N/A | -6.38% | -4.33% |
| OmniAb Competitors | -215.18% | -20.51% | -13.03% |
Volatility and Risk
OmniAb has a beta of -0.54, suggesting that its share price is 154% less volatile than the S&P 500. Comparatively, OmniAb’s peers have a beta of 5.74, suggesting that their average share price is 474% more volatile than the S&P 500.
Analyst Ratings
This is a summary of recent ratings for OmniAb and its peers, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| OmniAb | 0 | 0 | 9 | 0 | 3.00 |
| OmniAb Competitors | 39 | 672 | 1153 | 29 | 2.62 |
OmniAb presently has a consensus price target of $10.00, suggesting a potential upside of 76.99%. As a group, “Commercial physical research” companies have a potential upside of 14.28%. Given OmniAb’s stronger consensus rating and higher probable upside, equities research analysts plainly believe OmniAb is more favorable than its peers.
Summary
OmniAb beats its peers on 7 of the 13 factors compared.
About OmniAb
OmniAb, Inc., a biotechnology company, engages in the provision of therapeutic antibody discovery technologies in the United States. The company's discovery platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTau, which features unique structural attributes of cow antibodies for complex targets. The company was founded in 2012 and is headquartered in Emeryville, California.
Receive News & Ratings for OmniAb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OmniAb and related companies with MarketBeat.com's FREE daily email newsletter.
